Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer
The use of of CDK4/6 inhibitors to treat patients with TNBC is limited by loss of Rb. Here, the authors show that a combination of CDK4/6 inhibitor and EGFR inhibitor is effective against DEDD-overexpressing TNBC, independent of Rb status.
Guardado en:
Autores principales: | Yingjia Ni, Keon R. Schmidt, Barnes A. Werner, Jenna K. Koenig, Ian H. Guldner, Patricia M. Schnepp, Xuejuan Tan, Lan Jiang, Misha Host, Longhua Sun, Erin N. Howe, Junmin Wu, Laurie E. Littlepage, Harikrishna Nakshatri, Siyuan Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6cd4e5da2a3943ceb86081cf1bcee7ae |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Aged Breast Extracellular Matrix Drives Mammary Epithelial Cells to an Invasive and Cancer‐Like Phenotype
por: Gokhan Bahcecioglu, et al.
Publicado: (2021) -
Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
por: Qingfei Wang, et al.
Publicado: (2019) -
The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
por: Stijn Moens, et al.
Publicado: (2021) -
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
por: Brian D. Lehmann, et al.
Publicado: (2021) -
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
por: Yves Boucher, et al.
Publicado: (2021)